$XBI $135 -2%
Covid Updates
$RVVTF +6% Research agreement with UCSF for Bucillamine as potential treatment for severe Covid-19. source
$NVAX -15% Initiated pediatric expansion of Phase 3 trial of NVX-CoV2372 in patients 12-17 years. source
$EIGR +2% Peginterferon Lambda to be added to ongoing Phase 3 TOGETHER platform study in outpatients with COVID-19. source
$COCP +7% Aggressively developing novel coronavirus protease inhibitors (lead candidate CDI-45205) for prophylactic and therapeutic use; likely to be effective against new variants. source
$MRNA +4% WHO issued EUL for COVID-19 vaccine; supply agreement with Gavi to delivery vaccine to lowest income countries. source
$OCGN +29% COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant. source
$VXRT -25% (+23% AH) A Phase II trial of VXA-CoV2-1 expected to start mid-year 2021 instead of 2Q; provided data comparing T-cell responses of VXA-CoV2-1 to other vaccines. source
$VXRT -25% (+23% AH) New data suggests broad cross-coronavirus activity. source
Pipeline Updates
$TARS +4% Presents updated data from ATLAS and Europa studies of TP-03 in Demodex blepharitis at ARVO 2021. source
$MRUS +9% First patient dosed in ph 1/2 trial of MCLA-129 in advanced lung cancer and other solid tumors. source
$CYDY -1% On track for rolling submission of Vyrologix BLA in July 2021. source
$CYDY -1% Preparing a request for pre Breakthrough Therapy designation meeting ahead of expected Phase 3 trial for 22 solid tumor cancer indications. source
$NOVN -7%Final patient in B-SIMPLE4 trial completed last Week-12 visit. source
$AGLE +2% Completed patient randomization for phase 3 trial of pegzilarginase. source
$XBIT +1% Reached agreement to supply XB20-01 cancer drug to INSERM. source
$OCUL -3% FDA confirmed fulfilled all post-approval study requirements for ReSure Sealant. source
$KYMR -4% Presented positive late breaking data of IRAK4 to treat patients with hidradenitis suppurativa. source
$XOMA -4% First patient dosed in Phase 3 trial evaluating cetrelimab. source
$ZEAL +1% Published results from Phase 3 trial of dasiglucagon in Diabetes Care. source
$CFRX -8% Patent office issued Patent on 4/27/21 for CF-370. source
$FOLD +5% Completed Type B pre BLA meeting for AT-GAA; intends to complete rolling BLA submission in second quarter. source
$CLSD -3% Resubmitted NDA for XIPERE to treat macular edema associated with uveitis; expect six month review timeline. source
$AVRO -19% Initiating registration trial in mid 2022 to support future full approval of AVR-RD-01. source
$AMPH +3% FDA approval for morphine sulfate injection. source
$ADVM -5% Long term data from OPTIC clinical trial of ADVM-022 reported. source
$AZN +1% Farxiga approved to treat chronic kidney disease in patients at risk of progression. source
$OBSV -6% Posters presented at ACOG on safety parameters of linzagolix. source
$OYST -4% Presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01. source
$TXMD -5% ANNOVERA presented at 2021 ACOG meeting on menstrual bleeding profile data. source
$CABA -4% Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities. source
$KPTI +1% Seven abstracts highlighting data from solid tumor studies will be presented at the upcoming 2021 ASCO Annual Meeting taking place June 4-8, 2021. source
$CLNN +7% Patent office issued notices of allowance for two patent applications for platform technology. source
Financial Updates
$RYTM +2% First commercial sales of IMCIVREE completed in the first quarter. source
$KPTI +1% First quarter product sales of XPOVIO $21.7M. source